Numerous antibodies have been identified from HIV-1-infected donors that neutralize diverse strains of HIV-1. These antibodies may provide the basis for a B cell-mediated HIV-1 vaccine. However, it has been unclear how to elicit similar antibodies by vaccination. To address this issue, we have undertaken an informatics-based approach to understand the genetic and immunologic processes controlling the development of HIV-1-neutralizing antibodies. As DNA sequencing comprises the fastest growing database of biological information, we focused on incorporating next-generation sequencing of B-cell transcripts to determine the origin, maturation pathway, and prevalence of broadly neutralizing antibody lineages (Antibodyomics1, 2, 4, and 6). We also incorporated large-scale robotic analyses of serum neutralization to identify and quantify neutralizing antibodies in donor cohorts (Antibodyomics3). Statistical analyses furnish another layer of insight (Antibodyomics5), with physical characteristics of antibodies and their targets through molecular dynamics simulations (Antibodyomics7) and free energy perturbation analyses (Antibodyomics8) providing information-rich output. Functional interrogation of individual antibodies (Antibodyomics9) and synthetic antibody libraries (Antibodyomics10) also yields multi-dimensional data by which to understand and improve antibodies. Antibodyomics, described here, thus comprise resolution-enhancing tools, which collectively embody an information-driven discovery engine aimed toward the development of effective B cell-based vaccines.
as a search strategy. 4 Here, we describe a collection of technologies (Antibodyomics1-10) that provide information-rich analyses of the genetic and immunological processes controlling the development of effective HIV-1-neutralizing antibodies ( Fig. 1 ). Our description is not intended to represent a comprehensive summary of the field; rather, we have been asked by the editors of this volume to synthesize key aspects and to focus on our specific contributions and ideas. The majority of the Antibodyomics technologies incorporate data generated by massively parallel next-generation sequencing (NGS) of B-cell transcripts to enhance the resolution of the genetic information underlying antibody development. [5] [6] [7] [8] [9] We have also focused on technologies that allowed increased resolution of function relative to physical characteristics of antibodies and their targets. Together, these multi-dimensional technologies may afford sufficient resolution of antibodies and relevant immunological processes so they can be optimized for passive delivery or recapitulated by vaccination.
| ANTIBODYOMICS1
NGS of B-cell transcripts provides a means to interrogate the human antibody repertoire and to understand the B cell-based response to infection. We developed a software suite, Antibodyomics1, which can be used to organize cross-sectional NGS data containing millions of B-cell transcripts into distinct lineages and to map their development ( Fig. 2) . At its core, Antibodyomics1 assigns immunoglobulin germline genes to each NGS transcript, parses framework and CDR regions from each transcript, and uses sequence metrics to identify related antibodies in unrelated donors. Antibodyomics1 was originally developed to analyze 454 pyrosequencing data from HIV-1 infected donors 10 and can now accept sequencing data from the Illumina platform. 5, 11 Here, we highlight applications of the Antibodyomics1 pipeline.
The earliest application of Antibodyomics1 involved the discovery and characterization of antibodies from HIV-1-infected individuals. 9 Specifically, heavy chain sequences from antibodies of the VRC01
class [a multidonor class of antibodies directed at the CD4-binding site (12) ] were used to analyze B-cell transcripts from an HIV-1 infected donor (donor 74). This analysis yielded hundreds of new VRC01-class antibody sequences, with lineage analysis allowing the tracing back to earlier developmental intermediates. This initial application was aided by the sequence of VRC-PG04, a VRC01-class antibody identified by probe sorting of donor 74 B cells. 9 The results appeared promising enough that we undertook the de novo identification of VRC01-class antibodies in a new donor, C38, from which no VRC01-class antibodies were known. By using only template VRC01-class antibodies from non-C38 donors, we were able to identify VRC01-class heavy and light chains in donor C38. Reconstitution of identified heavy and light chain from donor C38 yielded antibodies capable of neutralizing diverse strains of HIV-1. 13 One of the pitfalls of NGS involving antibody repertoires is the loss of heavy and light chain pairing information. A solution to this pitfall implemented in Antibodyomics1 involves the phylogeny-based pairing of heavy and light chain transcripts.
14 Notably, we observed somatic variants positioned similarly in heavy and light chain phylogenetic trees, when paired and reconstituted, had reduced autoreactivity when compared to mismatched pairings [see Fig. 3C in (14) ]. These results indicate that the phylogenetically determined pairings approximate those in vivo, providing a partial solution to the heavy/light chain pairing pitfall.
We also used the Antibodyomics1 pipeline to define the developmental pathway of the 10E8 antibody from donor N152. 15 Heavy and light chain NGS data were processed bioinformatically to obtain somatic variants, and a combination of sequence sieving and CDR3-sequence filters were used to construct maximum-likelihood phy- The applicability of the Antibodyomics1 technology continues to expand, and the current Antibodyomics1.1 pipeline is available upon request (PDK, CS, LS). We recently used Antibodyomics1 to identify the sequences of vaccine-induced antibodies capable of neutralizing diverse group 1 and 2 influenza A viruses. 16 In addition to antibodies against other pathogens, Antibodyomics1 can in principle be applied to investigate diverse areas such as autoimmunity, inflammation, and B-cell disorders including lymphomas or IgA nephropathy. In principle, the B-cell record may contain information on the exposure to pathogens throughout the lifetime of an organism. How comprehensively one can sequence the B-cell compartment and how diverse B-cell transcripts are across donor populations remain areas of active research.
| ANTIBODYOMICS2
To add a temporal dimension to the analysis of B-cell repertoires, we reimagined the Antibodyomics1 pipeline. 13 Currently, the Longitudinal sampling of the antibodyome provides temporal resolution of antibody repertoire dynamics and of B-cell ontogenies 6, 7, 18 ( Fig. 3A-C) . The temporal dimension can also be leveraged to better understand key interactions with virus that helped drive antibody evolution [5] [6] [7] 19 ( Fig. 3D ), as well as intrinsic properties of antibody maturation 18, 20 (Fig. 3E) . Altogether, these analyses provide developmental insights with implications for vaccine design ( Fig. 3F ) and to enhance the functionality of natural antibodies for clinical use (Fig. 3G ).
The first antibody lineage to be studied with Antibodyomics2 was the CH103 lineage, a CD4-binding site-targeting antibody, 7 which was also analyzed in detail with software developed by Kepler and colleagues. 21 Transcripts of this lineage were isolated from four time points spanning 130 weeks, and used to infer the UCA and other intermediates. Analysis of antibody-virus co-evolution revealed that viral diversification around the CH103 epitope was important for the development of breadth and potency of neutralization by the CH103 lineage. A second antibody lineage, CH235, was later identified from the same donor 5, 22 ; longitudinal studies of this lineage revealed similarities to other CD4-binding site-directed lineages, which may help guide efforts to elicit this class of antibodies via vaccination. 5 Together, the longitudinal information from these three studies provided an indepth look at the antibody response to HIV in a single donor, including how multiple antibody lineages target similar epitopes and can interact to drive the emergence of neutralization breadth.
We have also used Antibodyomics2 to investigate the origins of the CAP256-VRC26 lineage, a V1V2-targeting broadly neutralizing antibody. 6, 19 We were able to identify autologous viruses that likely helped trigger lineage development and showed that toleration of early autologous escape mutants correlates strongly with the acquisition of breadth. 19 We also showed that the CAP256-VRC26 lineage shared developmental features with other V1V2-targeting antibodies, including the creation of a protruding loop by recombination and a propensity for early intermediates to interact with a specific subset of viral strains. Light tree F I G U R E 3 Antibodyomics2: Translating longitudinal samples into developmental pathways and maturation rates. Antibodyomics2 focuses on the longitudinal development of neutralizing antibody lineages, using (A) multiple deep-sequencing experiments across time (B) to reconstruct detailed ontogenies. These ontogenies can be used (C) to infer UCA and early intermediates, providing details on the emergence of desired features, such as heterologous neutralization; (D) to study co-evolution between an antibody lineage or lineages and the eliciting pathogen, revealing critical interactions that elicited the desired features; and (E) to observe intrinsic properties of antibody maturation, such as the evolutionary rate and how it changes over time. All of these analyses provide insights into antibody development which can be leveraged (F) to design better vaccines and (G) to improve naturally occurring antibodies for use as therapeutics. 
| ANTIBODYOMICS3
Antibody responses to HIV-1 infection are typically complex and polyclonal, targeting a variety of epitopes on the Env glycoprotein. As an alternative to purely experimental techniques, we developed a data analysis-based computational method for serologic analysis of HIV-infected individuals. 49 The method works as follows: we define an antibody neutralization fingerprint as the potency-dependent pattern with which a set of diverse HIV-1 strains is neutralized by a given monoclonal antibody. As we have shown that neutralization fingerprints are epitope-specific 49 Fingerprints of defined epitopes from donor cohorts + example, for donor CAP256, we observed that the CAP256-VRC26
lineage was the primary contributor to serum neutralization, likely indicating the lack of other major broadly neutralizing specificities. 6 Alternatively, an identified antibody lineage may not contribute substantially to serum neutralization, which may be dominated by
other, yet to be discovered, specificities. The fingerprinting analysis can therefore lead to a better understanding of the complexity of polyclonal sera and the effects different component antibodies can have on polyclonal neutralization; (iii) While the sera from many donors appear to contain antibodies that are similar to already known specificities, new epitopes continue to be discovered. 27, 30, 33 When an antibody targeting a new epitope is discovered, the neutralization fingerprinting approach can be used to screen HIVinfected sera for neutralization signals matching the new epitope, therefore both guiding efforts for identifying additional antibodies targeting this epitope, as well as providing an estimate of the overall prevalence of such antibodies in infected donors. The latter can be an important factor when evaluating targets for epitope-specific vaccine design, with the idea that epitopes that are more prevalent in the population may be better vaccine candidates; 27 and (iv) In addition to the analysis of polyclonal sera, the neutralization fingerprinting approach has been useful for the characterization of the epitope specificities of monoclonal antibodies. For example, such analysis can reveal connections between antibody genotype, structural mode of recognition, and neutralization fingerprint similarity. 39 Furthermore, the fingerprinting analysis can help trace the neutralization evolution of different members of the same antibody lineage. 5, 18 Overall, the neutralization fingerprinting method for serologic analysis of antibody responses to HIV-1 infection has proven to be a useful tool in the armamentarium of techniques available to researchers. 5, 6, 18, 27, 30, 32, 39, [49] [50] [51] The source code for Antibodyomics3 is provided as a supplement to Georgiev et al. 49 , and updated versions can be requested from the authors. Additional improvements in the computational methodology should further enhance the usefulness of the fingerprinting approach by improving the accuracy and reliability of the predictions. As neutralization data for large HIV-infected cohorts become available, the fingerprinting technology can play an important role in deciphering the elicitation of broadly neutralizing antibody specificities at the population level, and can therefore help guide efforts for epitope-specific vaccine design. More generally, as indicated by initial analysis of influenza antibody fingerprints, 16 the fingerprinting technology should be extendable to other viruses with high levels of antigen sequence diversity, such as influenza A and hepatitis C viruses. The first use of high-throughput paired V H :V L sequencing with HIV-1-directed broadly neutralizing antibodies helped elucidate the early ontogeny of the CAP256-VRC26 antibody, which targets the V1/V2 region of the fully assembled HIV trimer. 6 In this study, lon- ]. In addition to providing vaccine templates, quantification of the prevalence of these multidonor class broadly neutralizing antibodies in sera could potentially allow their use as biomarkers in vaccine development (Fig. 6 ).
| ANTIBODYOMICS4
In Antibodyomics5, we delineate the frequency of multidonor class antibodies in target populations, 12 derive sequence signatures for the multidonor class, 12, 39 and use these signatures to quantify the prevalence of the multidonor antibody class in the B-cell compartment. 12, 39 This information can then be used to design or to select immunogens that maximize the elicitation frequency of target antibodies. [59] [60] [61] 67 In the first application of Antibodyomics5, we used both fre- We have also applied Antibodyomics5 to the quantification of multidonor class antibodies that neutralize both group 1 and group 2 influenza A viruses. 16 We delineated antibody sequence signatures and quantified antibodies that satisfy these sequence signatures in NGS datasets from multiple donors with different vaccination histories. 52, 68 Notably, one vaccination regimen from the VRC 310 trial involving immunization with a diverse H5 hemagglutinin increased the frequency of two multidonor classes by over 100-fold, 16 despite titers too low to detect in sera. This demonstrates the exquisite sensitivity of B-cell quantification, where one transcript in about one million can be detected-a more sensitive quantification than allowed by assessment of serum neutralization.
Overall, the quantification afforded by Antibodyomics5 of multi- Thus, antibody-gene mutability (the non-uniform mutation frequency and nucleotide substitution bias within the antibody variable region) leads to a distribution of substitution probabilities at the nucleotide level. As a consequence, patterns of amino acid substitutions are also affected. 78 The use of NGS to sample antibody repertoires provides a sufficiently large basis set of antibody transcripts from which a mutation spectrum for each position of each germline V gene can be compiled (Fig. 7 , left and middle). By applying this method, we found that antibodies originating from the same germline V gene share a substantial percentage of amino acid mutations in the V region, irrespective of antigen specificity. 5 This suggests that intrinsic mutability modulates the positions and identities of substitutions in the antibody variable region. This also suggests that functional selection is not the sole (or even the dominant) factor regulating antibody maturation process. These conclusions are supported by our recent observations in an HIV Env vaccination study that high-frequency somatic mutations observed in elicited antibodies were also high-frequency mutations in non-HIV neutralizing antibodies. 61 One implication of these findings is that mutations with very low occurrence frequency, but are functionally critical, may constitute dominant roadblocks to elicitation. 79 Ongoing developments include construction of new in silico models of the mutation space to achieve improved simulation of the antibody maturation process. Currently, the construction of mutational profiles for Antibodyomics6 is implemented as an extension of Antibodyomics2.1, through scripts selecting appropriate antibody repertoires to build gene-specific mutational profiles. 
| ANTIBODYOMICS6

| ANTIBODYOMICS7
Molecular dynamics (MD) simulations provide a means to extend atomic-level structural information, which can be helpful in multiple cases including (i) the docking of an antibody to an antigen when the high-resolution complex structure is unavailable; (ii) the conformation of the antigen, especially for mobile regions where crystallographic information provides only a snapshot; and (iii) the accessibility of antibody to protein surface, especially with glycopeptide antigens. In Antibodyomics7, we apply MD to the analyses of antigen conformation and of antibody-antigen interactions (Fig. 8) .
F I G U R E 6 Antibodyomics5: Quantification of multidonor antibody responses and class-guided design. Broadly neutralizing antibodies that arise in multiple donors and share common features of antigen recognition and B-cell ontogeny may have utility as vaccine templates due to the potential for similar antibodies to be elicited by a common immunogen in the general population. In Antibodyomics5, we delineate the frequency of multidonor class antibodies, derive sequence signatures, and quantify the prevalence of a given multidonor antibody class in the B-cell compartment. This information can be used to guide the design or the selection of vaccine candidate aimed at "re"-eliciting the target broadly neutralizing antibody classes. (11)].
In terms of antigen conformation, dynamic properties may have significant effects, which may not be apparent in static X-ray structures. In particular, highly mobile regions and molecules exposed to F I G U R E 7 Antibodyomics6: Impact of gene mutability and substitution bias on the development of broadly neutralizing antibodies. In Antibodyomic6, we focused on the investigation of position-specific mutation probability and substitution bias of the antibody variable region (Top row), the knowledge derived from which will be used to address a series of immunological questions. Briefly, we sequence antibody repertoires from multiple donors with NGS and process transcripts to identify antibody clones (Top row left and middle). We choose a representative transcript from each clone and construct a mutation profile for each germline V gene using all clones identified (Top row right). We then use the mutation profiles and in silico models to understand the mutation patterns observed in bnAbs and to evaluate the likelihood of re-eliciting similar mutations by vaccination (Bottom row)
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Gene-specific mutation profile solvent are rarely defined structurally, and classical MD has proven to be a valuable tool to probe dynamics of such molecules 81, [83] [84] [85] . For example, the eight amino acids at the N-terminal of the fusion peptide of HIV-1 Env in its closed prefusion state are not visualized in most crystal structures. 32, 86, 87 However, we observed antibody VRC34 to recognize these eight residues as the primary determinant of binding. 30 MD of the prefusion closed Env trimer revealed this eight amino acid region to be highly mobile with average solvent accessibilities in the MD simulations that correlated with VRC34 recognition [see nearly 50% of its mass. [88] [89] [90] [91] We used MD to characterize the properties of the glycan shield and to identify specific glycans that obstruct antibody access to known sites of vulnerability. 
| ANTIBODYOMICS8
One of the fastest growing areas of biotherapeutics is the use of monoclonal antibodies, especially in the treatment of cancer, autoimmune disorders, and infectious diseases. 92 One roadblock to achieving effective therapies is the long and costly process of antibody optimization, which may require years of effort. Computational approaches may aid in this process, but their effective implementation has been difficult because current tools fail to yield predictions of sufficient accuracy.
Antibodiomics8 aims to develop and apply computational methods that provide accurate biophysical characterization and improved functional efficacy of antibodies directed against HIV-1.
As discussed in the prior section, MD simulations are widely used to define the conformational space of macromolecules, 83 
| ANTIBODYOMICS9
As Previously we showed that arginine scanning of antibody surfaces could be used to identify paratope residues that interact with antigen. 11, 102 In Antibodyomics9, we extend this methodology to a surface-matrix approach in which a collection of individual surface mutations are generated and their properties are assessed (Fig. 10) . 
| ANTIBODYOMICS10
As random searching for functional antibodies to counter the nearinfinite diversity of potential immunogens may be problematic, well-configured antibody repertoires may be key to protective humoral immunity. 111 The human immune system, for example, typically responds to a novel antigen by generating antigen-specific antibodies within just a few weeks. and small hydrophilic residues on the antibody. 114 One implication of these insights is that a synthetic antibody library bearing paratopes with diverse structural contours-enriched with aromatic residues among short chain hydrophilic residues-should be capable of recognizing the surfaces of most protein antigens through binding to common physicochemical features: carbon atoms and polar backbone groups.
114
We have analyzed the antigen recognition capabilities of mouse antibody repertoires by examining the functionality of corresponding synthetic phage-displayed antibody libraries-including libraries specifically enriched with aromatic residues among short chain hydrophilic residues (Fig. 11) . 
| CONCLUSION
The resolution-enhancing multi-dimensional technologies described here yield information-rich datasets that can synergize with one another to provide in-depth understanding of the development of broadly neutralizing immunity to HIV-1, both in the context of natural infection (Fig. 1B, upper panels) and in active or passive immunization (Fig. 1B, lower panels) . In particular, Overlaid are the resolution-enhancing Antibodyomics technologies, highlighting appropriate points of application and the immunological processes that they inform. In addition to ontogeny-based strategies of vaccine design, the Antibodyomics technologies described here can be applied to other vaccine strategies. For example, Antibodyomics1, 2, and 4 can be applied to any vaccine strategy for which lineage information is crucial. Similarly, Antibodyomics5 and 6 generate statistical information on elicited lineages and their SHM requirements, and these technologies should inform lineage-based strategies. Meanwhile, Antibodyomics3 provides information on the specificity of serum, with general applicability to many vaccine-related problems. Other Antibodyomics technologies may have more specific applications, such as Antibodyomics8 and 9, which involve antibody recognition and improvement, and Antibodyomis10, which is designed to provide specific insight into confounding factors such as autoreactivity, T-cell help, and commonality of protruding loops. Table 1 summarizes the Antibodyomics technologies and their software embodiments.
We note that applications of Antibodyomics technologies are not unique to the investigations of immunity to HIV-1. Indeed, we recently applied Antibodyomics1 to understand the induction of antibodies capable of neutralizing diverse group 1 and group 2 subtypes of influenza A virus, and also used Antibodyomics3 to classify reconstituted neutralizing functionalities. 16 More generally, the purpose of the Antibodyomics technologies is to afford a data-rich view of the genetic and immunological processes controlling B cell-lineage development. The information-rich output may also provide insights into the evolution and specific immunological events allowing for lineage development. When combined with atomic-level structural information on antibodies, antigens, and their complexes, a similarly data-rich view of the chemistry of antibody/antigen interaction can be obtained. Overall, the Antibodyomics technologies described here comprise an information-rich discovery platform, which has been developed specifically for HIV-1, but should be broadly applicable to other systems that require an understanding of antibody lineages. 
